Should you buy Inogen stock? (NasdaqGS:INGN). Let's see how it does in our automated value investing analysis system.
(Inogen stock price per share)
||INGN Fair Price
(based on intrinsic value)
|INGN Safety Price (based on a variable margin of safety)||$19.95|
|PE Ratio versus Sector||197% higher than other Healthcare stocks|
|PE Ratio versus Industry||605% higher than other Medical Devices stocks|
|Free Cash Flow Jitter||37%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 749,558 shares shorted. With 22,541,991 shares available for purchase and an average trading volume over the past 10 trading days of 158,980, it would take at least 4.715 days for all of the short holders to cover their shorts.
We believe that Inogen may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Inogen looks like a price in the fair value range. Based on our analysis—if the company keeps making money the way it has been—you could be looking at a good stock. See Before You Buy for your next steps.
Does Inogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles